Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and persistence, and higher response rates [50% complete remission (CR), 72% overall response rate (ORR)] than patients who received Cy-based lymphodepletion without Flu (8% CR, 50% ORR). The CR rate in patients treated with Cy/Flu at the maximally tolerated dose was 64% (82% ORR; n = 11). Cy/Flu minimized the effects of an immune response to the murine single-chain variable fragment component of the CAR, which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu. Severe cytokine release syndrome (sCRS) and grade ≥3 neurotoxicity were observed in 13 and 28% of all patients, respectively. Serum biomarkers, one day after CAR-T cell infusion, correlated with subsequent sCRS and neurotoxicity. Immunotherapy with CD19 CAR-T cells in a defined CD4(+)/CD8(+) ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“prolonged in vivo persistence of CAR-T cells has been correlated with the depth and durability of clinical responses [32, 36].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [36]
In the citing paper
“It is also known that lymphodepletion and the establishment of an optimal homeostatic cytokine environment is critical for robust CAR T-cell expansion and function.4,44,45”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · cited 3×
“We observed that treatment with the same lymphodepletion and CD19 CAR-T cell immunotherapy regimen resulted in lower CR rates in NHL and chronic lymphocytic leukemia (CLL) patients compared to B-ALL patients (1, 25).”
BackgroundResultSelf-citation
Research works printed but not linked: 2
- Gordis L Epidemiology 4 Philadelphia Saunders 2008
- Yeh ST Using trapezoidal rule for the area under a curve calculation Proceedings of the Twenty-Seventh Annual SAS User Group International (SUGI) Conference. Paper 229–27 2002
Cited by
Items 801–900 of 999
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy
Wang, M., Jia, L., Dai, X., & Zhang, X. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13621 · Cited by 10
“Turtle et al . found that the cyclophosphamide (Cy) and flu-darabine (Flu) treatment dramatically improved the therapeutic effect of CAR-T cells therapy on relapse-d/refractory B cell NHL cancer [95,153].”
Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells
Narra, R. K., Peshin, S., & Dhakal, B. (2024) · Acta Haematologica · doi:10.1159/000543265 · Cited by 5
“Host cellular immunity speci fi c to speci fi c to peptide from FMC63 murine scFv was postulated to be responsible for this in eighty percent of the patient who cound not expand [68].”
Yang, H., Hu, Y., Kong, D., Chen, P., & Yang, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109542 · Cited by 5
Castagna, L., Bono, R., Tringali, S., Sapienza, G., Santoro, A., Indovina, A., Tarantino, V., Noto, L., Maggio, A., & Patti, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1072192 · Cited by 4
Ligon, J. A., Ramakrishna, S., Ceppi, F., Calkoen, F., Diorio, C. J., Davis, K. L., Jacoby, E., Gottschalk, S. M., Schultz, L. M., & Capitini, C. M. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.012 · Cited by 5
Li, P., Dong, N., Zeng, Y., Liu, J., Tang, X., Wang, J., Zhang, W., Ye, S., Zhou, L., Chang, A. H., et al. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0740-6 · Cited by 4
Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults
Kimble, E. L., & Cassaday, R. D. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1964022 · Cited by 4
Traitement par CAR-T des leucémies aiguës de l'adulte
Rahal, I., Cabannes‐Hamy, A., & Boissel, N. (2018) · Bulletin du Cancer · doi:10.1016/s0007-4551(19)30046-3 · Cited by 5
Locke, F. L., Nikiforow, S., Frigault, M. J., Maloney, D. G., Davila, M. L., Miklos, D. B., Lin, Y., Vong, J., Shah, N. N., Neelapu, S. S., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.11.004 · Cited by 3
Yu, M., Yang, T., Ding, S., & Hu, Y. (2025) · American Journal of Hematology · doi:10.1002/ajh.70131 · Cited by 4
Fettiplace, A., Regev, A., Kiazand, A., Heinzel-Pleines, U., Bahjat, M., Garg, A., Kikuchi, L., Li, H., Hamidi, A., Alpers, D., et al. (2025) · Drug Safety · doi:10.1007/s40264-025-01635-5 · Cited by 6
“Typically, fludarabine/high dose cyclophosphamide combination is used [141, 142].”
ADA1-Driven Metabolic Refueling Enhances CAR T Cell Therapy for Solid Tumors
Song, A. W., & Song, X. (2025) · Cancers · doi:10.3390/cancers18010034 · Cited by 4
“CAR T cell therapy has marked a major advancement in oncology, especially for patients with refractory B cell hematologic malignancies [1–8].”
Rewiring immunity: CAR-T cells as a paradigm shift in hematologic oncology
Janes, M. A., Zhao, L., Bruton, L. G., Schmidt, A. A., Parker, J. M., Wakefield, M. R., & Fang, Y. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105281 · Cited by 4
Hu, C., Zhang, H., Zhu, H., Fan, J., Chen, D., Zhu, S., Li, C., Sun, J., Chen, Y., Ren, J., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08656-7 · Cited by 3
Yi, R., Zhang, Z., Yang, Y., & Zhu, H. (2026) · Cancer Innovation · doi:10.1002/cai2.70053 · Cited by 3
“This process supports robust CAR T‐cell expansion, enhances CAR T‐cell persistence, and exerts direct cytotoxic effects on the TME, collectively contributing to improved clinical outcomes [9, 172].”
Management of haemostatic complications of chimaeric antigen receptor T‐cell therapy
Swan, D., & Thachil, J. V. (2022) · British Journal of Haematology · doi:10.1111/bjh.18045 · Cited by 3
Incorporating Immunotherapy with Radiotherapy for Lymphomas
Strati, P., & Spiotto, M. T. (2023) · Lymphatics · doi:10.3390/lymphatics1030018 · Cited by 5
“The favorable impact of lymphodepletion is mediated by multiple biological mechanisms, including but not limited to the elimination of sinks for homeostatic cytokines, mainly interleukin-7 (IL-7) and IL-15, and the eradication of regulatory T cells and myeloid-derived suppressor cells [71–73].”
BackgroundCAR T therapy from haematological malignancies to aging‐related diseases: An ever‐expanding universe
Ramoni, D., Montecucco, F., & Carbone, F. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14203 · Cited by 3
“While leukodepletion effectively reduced host's immune response against the transgene product, 27 long-term persistence of CAR T cells may be insufficient, due to factors, such as the term recovery in host immune system response, the lack of target antigen to maintain CAR T cell population after…”
BackgroundOptimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia
Gamal, W. M., Mediavilla-Varela, M., Uriepero, A., Pinilla-Ibarz, J. A., & Sahakian, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126324 · Cited by 3
Mousavi, S.-R., Khazaee‐Nasirabadi, M. H., Seyedmehdi, M. S., Bazı, A., & Khalilabadi, R. M. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2438802 · Cited by 3
“…is thought to depend on in vivo durability and cAR t cell expansion, especially when it comes to cancers like Acute lymphocytic leukemia (All) that require intensive treatment. the immune system’s anti-transgene responses in the host’s body may be the reason why cAR t cells fail to persist [46,47].”
Kong, L.-Q., Chen, S., Cui, X., Hu, Y., Wang, L., Zhu, J.-Y., Guan, L.-X., Wang, B., Yang, L., Chen, K., et al. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05347-3 · Cited by 7
Si, C., Li, Y., Wang, Y., Gao, J., & Ma, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167890 · Cited by 3
“The expansion and persistence of CAR cells in vivo critically influence tumor therapy efficacy, particularly for malignancies requiring long-term treatment [56].”
Lai, X., Sun, Y., Chang, L. J., Ma, Y. R., Gu, X. Z., Yao, X. M., Nie, B., Wen, Y., Zhang, X. M., Jiang, Y. X., et al. (2020) · Bioengineered · doi:10.1080/21655979.2020.1791597 · Cited by 3
“CSF), monocyte chemotactic protein (MCP)-1, ferritin, C-reactive protein (CRP) and MIP-1α, etc [4,13,14].”
BackgroundMécanismes de résistance et d’échappement aux cellules CAR-T
Grinda, T., Brouard, J., Tran, D., & Rubio, M. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.09.002 · Cited by 3
Cell Types Used for CAR Generation
DeSelm, C. J. (2022) · Cancer Drug Discovery and Development · doi:10.1007/978-3-030-87849-8_4 · Cited by 2
Jain, M. D., Coney, P., & Locke, F. L. (2021) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_10 · Cited by 3
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
Keller, A. L., Sherbenou, D. W., Forsberg, P. A., & Mark, T. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925818 · Cited by 4
Atanackovic, D., Iraguha, T., Omili, D. O., Avila, S. V., Fan, X., Kocoglu, M. H., Gebru, E., Baker, J. M., Dishanthan, N., Dietze, K. A., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.01.006 · Cited by 3
Xin, X., Lin, L., Yang, Y., Wang, N., Wang, J., Xu, J., Wei, J., Huang, L., Zheng, M., Xiao, Y., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.01.012 · Cited by 3
Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022
Shen, J., Li, J., Lei, Y., Chen, Z., Wu, L., & Lin, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30955 · Cited by 4
Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas
Hu, B., Korsos, V., & Palomba, M. L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394057 · Cited by 4
Zhang, Z., Zheng, J., Liang, Y., Wu, Q., Ding, C., Ma, L., & Su, L. (2025) · BMC Cancer · doi:10.1186/s12885-025-14227-4 · Cited by 4
“Splenic hemorrhage is a bleeding event, and studies have shown that bleeding events after CAR-T cell therapy are likely to lead to patient death [1, 48, 49].”
CAR T cells find strength in polyfunction
Davila, M. L. (2018) · Blood · doi:10.1182/blood-2018-06-858712 · Cited by 4
CAR-T cells : lymphocytes exprimant un récepteur chimérique à l’antigène
Chabannon, C., Bouabdallah, R., Fürst, S., Granata, A., Saillard, C., Vey, N., Mokart, D., Fougereau, E., Lemarié, C., Mfarrej, B. G., et al. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2018.12.002 · Cited by 3
Dave, P., Vela, E. P., & Cancarevic, I. (2021) · Cureus · doi:10.7759/cureus.17709 · Cited by 3
“[26] R/R NHL 37 20 corticosteroids 4 CR”
BackgroundMethodInfluentialYust‐Katz, S., Khagi, S., & Gilbert, M. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00045-1 · Cited by 3
A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction
Chávez, J. C., & Locke, F. L. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.005 · Cited by 3
“Earlier reports from the National Cancer Institute (NCI), and other groups, demonstrated that second generation anti-CD19 CAR T cells can safely put refractory DLCBL into remission.(4,5) These results were replicated in the multicenter phase I portion of the Zuma-1 trial testing KTE-C19 (now called axicabtagene cilole…”
BackgroundResultA cell surface clicked navigation system to direct specific bone targeting
Kim, Y. J., Zhang, Z., Shim, J., Lee, T. S., & Tung, C. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.12.037 · Cited by 3
[Efficacy of anti-CD19 CAR-T cell therapy in 10 refractory recurrent B cell malignancies].
Bao, F., Hu, K., Wan, W., Tian, L., & Jing, H. (2018) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2018.06.003 · Cited by 3
“[16] Turtle CJ, Hanafi LA, Berger C, et al.”
BackgroundNot So FASt: Tumor Cells Resisting Death Drive CAR T-cell Dysfunction
Green, M. R., & Neelapu, S. S. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0037 · Cited by 3
PiggyBac-modified CD19-expressing 4T1 cell line for the evaluation of CAR construct.
Hu, H., Wang, R., Zhang, Z., et al. (2019) · PubMed · Cited by 3
Mu, J., Liu, M., Wang, J., Meng, J., Zhang, R., Jiang, Y., & Deng, Q. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/145948 · Cited by 3
CAR T-Cell Therapies in Mantle Cell Lymphoma, Hints of Cure
Wang, M. L. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(21)01262-3 · Cited by 3
Genomic Strategies for Personalized Cancer Therapy
Dudek, A. Z., Baxstrom, K., Bharadwaj, S., Blaes, A. H., Kulkarni, A. A., Lou, E., Nehru, V. M., Rabinovich, E., Shergill, A. P., & Viner, M. (2020) · Wiley eBooks · doi:10.1002/9781119432487.ch1 · Cited by 3
Adoptive Cell Therapy for Pediatric Solid Tumors
Hont, A. B., & Bollard, C. M. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041636 · Cited by 3
Hu, J., Feng, C., He, L., & Wang, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13578 · Cited by 6
“Furthermore, anti‑il‑6 therapy does not affect the expansion or efficacy of CAR T cells (38,48,65,66). consequently, anti‑il‑6 is the preferred treatment option for patients with severe crS (48,66). n umerous case reports demonstrate the efficacy of tocilizumab (an IL‑6 monoclonal antibody) in…”
Revolutionizing the treatment of cancer using CAR T Cells and Bispecific Antibodies
Medapati, S., Haripriya, B. V. S. L., Dummari, P. J., Mugada, V., Medapati, R. V., & Yarguntla, S. R. (2024) · Palestinian medical and pharmaceutical journal/Palestinian medical & pharmaceutical journal · doi:10.59049/2790-0231.10.1.2262 · Cited by 2
CAR T-Cell Therapy: Considerations for the Inpatient Dermatologist
Quan, I. L., Trupiano, N. E., Park, J., Nguyen, C. V., & Zheng, L. (2025) · Current Dermatology Reports · doi:10.1007/s13671-025-00472-0 · Cited by 2
“Prior to infusion, the patient receives lymphodepleting conditioning chemotherapy (e.g., fludarabine and cyclophosphamide) [ 9] within a week before CAR T infusion to create an immuno-logically favorable environment and cytokine profile.”
Kimble, E. L., Wright, J. H., Torkelson, A., Kirchmeier, D. R., Braathen, K., Ruff, R. O., Shimp, K. R., Seaton, B. W., Gauthier, J., Kolokythas, O., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013123 · Cited by 3
Liang, Z., Wang, Y., Zhang, X., Chen, Y., Yu, G., Guo, X., Ma, Y., & Wang, J. (2026) · Biosensors · doi:10.3390/bios16010041 · Cited by 3
“For example, subtype-specific expression of Cluster of Differentiation (CD) molecules on CD4 + /CD8 + T cells directly influences antigen recognition sensitivity and the duration of immune activity, and is a critical determinant of CAR-T therapeutic efficacy and functional heterogeneity [4,5].”
CAR-T cells in the treatment of neurological autoimmune diseases
Vonberg, F. W., Schroeder, B. E., Edwards, A. E., Sun, B., Keh, R. Y. S., Ashraghi, M. R., Joe, D., Gorgoraptis, N., Rees, J. H., Davies, N. W. S., et al. (2026) · Practical Neurology · doi:10.1136/pn-2025-004890 · Cited by 3
Zhang, X., Aimaiti, G., Guan, Y., Sha, Y., Zhou, W., Shen, J., Zhao, B., & Yuan, W. (2026) · Advanced Science · doi:10.1002/advs.202518547 · Cited by 10
“Clinical dosing regimens vary across institutions; the commonly used protocols involve intravenous infusion of dexamethasone (10 mg every 6 h) or methylprednisolone (1– 2 mg/kg/day), with a gradual tapering of the dosage over 3–5 days based on the patient’s clinical response [ 178 ].”
Ying, H., Pan, Y., Zhu, X., & Xuan, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1778197 · Cited by 2
“Clinically, CRS manifests as fever, fatigue, myalgia, and anorexia, and severe cases may involve multiple organ systems (60, 61).”
CAR-T Cells: Next Generation Cancer Therapeutics
Balakrishnan, A. (2018) · Journal of the Indian Institute of Science · doi:10.1007/s41745-018-0062-8 · Cited by 2
Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma
Perica, K., Palomba, M. L., & Brentjens, R. J. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.23 · Cited by 2
“formed follicular lymphoma (tFL), FL, and mantle cell lymphoma (MCL).(17) More recently, researchers at the University of Pennsylvania reported their single‐center experience with a CD19 CAR con-”
BackgroundWhen to Refer a Patient for CAR T-Cell Therapy
Orellana-Noia, V. M., Portell, C. A., & Ballen, K. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00001-9 · Cited by 2
Mechanisms of Resistance and Relapse After CAR-T Cell Therapy
Selli, M. E., Dalal, P., Neelapu, S. S., & Singh, N. (2022) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_12 · Cited by 4
Optimizing Blood Stem Cell Transplants Through Cellular Engineering
Soh, K. V. Q. Y., & Hwang, W. Y. K. (2022) · BLOOD CELL THERAPY / The official journal of APBMT · doi:10.31547/bct-2021-008 · Cited by 1
(2021) · Frontiers research topics · doi:10.3389/978-2-88966-718-5 · Cited by 3
Immunohistochemical Detection of 5T4 in Renal Cell Carcinoma
Miller, C. P., Shokri, F., Akilesh, S., Xu, Y., Warren, E. H., Tykodi, S. S., & Tretiakova, M. (2023) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001101 · Cited by 2
The Power of Imaging Techniques in CAR-T Cell Therapy Enhancement: Revolutionizing Cancer Treatment
Karimi, H., Mohammadi, S., Jolfayi, A. G., Lavafian, A., Khalili, E., Khalaj, F., Khojasteh‐Kaffash, S., & Keshavarz, E. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_352 · Cited by 2
Yu, X., Liu, C., Hu, S.-Z., Yuan, Z.-Y., Ni, H.-Y., Sun, S., Hu, C., & Zhan, H.-Q. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03774-0 · Cited by 2
Cardiovascular Toxicity of CAR-T Cell Therapy: A Literature Review
Murtuzaliev, S. M., Salakheeva, E. Y., Kardovskaya, S. A., Kirichenko, Y. Y., Сидерко, Е. А., Belenkov, Y. N., & Ilgisonis, I. S. (2024) · Clinical oncohematology · doi:10.21320/2500-2139-2024-17-4-404-414 · Cited by 3
Sierro-Martínez, B., Guijarro-Albaladejo, B., Fernández-Cisnal, R., Rodríguez‐Gil, A., Hernández-Díaz, P., de la Rosa-Garrido, M., Carrasco-Brocal, I., Lara‐Chica, M., Gómez, V. E., Muñoz-García, R., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06899-0 · Cited by 3
Immunotransplant: Preventing Unintended Consequences
Ansell, S. M. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0977 · Cited by 2
Perspectives d’évolution et d’utilisation des cellules CAR-T
Genebrier, S., & Tarte, K. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.04.021 · Cited by 3
Making urothelial carcinomas less immune to immunotherapy
Ramos, J., & Yu, E. Y. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.10.007 · Cited by 2
“[40] Turtle CJ, Hanafi LA, Berger C, et al.”
BackgroundDetermination of cell expansion and surface molecule expression on anti‐CD3/28 expanded CD4+ T cells
Thitilertdecha, P., Poungpairoj, P., Tantithavorn, V., Ammaranond, P., & Onlamoon, N. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12808 · Cited by 2
CAR-T Cell Clinical Trials Experience – Past, Present and Future
Azam, U., & Sridharan, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00012-1 · Cited by 2
Martino, M. V., Macheda, S., Aguglia, U., Arcudi, L., Pucci, G., Martino, B., Altomonte, M., Rossetti, A. M., Cusumano, G., Russo, L., et al. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1974394 · Cited by 2
Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care
Khazal, S. J., & Mahadeo, K. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-74698-2_200-1 · Cited by 2
Hahn, W. O., Hill, J. A., & Kublin, J. G. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000826 · Cited by 3
Han, Z., Ma, X., & Ma, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28098 · Cited by 3
Kitamura, W., Asada, N., Ikegawa, S., Fujiwara, H., Kamoi, C., Ennishi, D., Nishimori, H., Fujii, K., Fujii, N., Matsuoka, K., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.2556-23 · Cited by 2
“The cellular composition of CAR T cell products is heterogeneous, and the frequency of CD4 + and CD8 + T cell subsets in patient blood varies markedly among individuals (39, 50).”
BackgroundBassil, C., & Khimani, F. (2020) · Journal of Onco-Nephrology · doi:10.1177/2399369320953163 · Cited by 2
Solid tumor-on-chip model for efficacy and safety assessment of CAR-T cell therapyPreprint
Maulana, T. I., Teufel, C., Cipriano, M., Lazarevski, L., van den Hil, F. E., Orlova, V. V., Koch, A., Alb, M., Hudecek, M., & Loskill, P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.13.548856 · Cited by 3
Response Assessment and Post–CAR T-Cell Therapy Management
Taraseviciute, A., Pulsipher, M. A., & Wayne, A. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00009-3 · Cited by 1
Pensato, U., Muccioli, L., Taurino, D., Pondrelli, F., Asioli, G. M., Philippis, C. D., Mannina, D., Bagnato, G., Marcheselli, S., Zinzani, P. L., et al. (2024) · Neuro-Oncology Practice · doi:10.1093/nop/npae128 · Cited by 2
Varela-González-Aller, J., Sánchez-Salinas, M. A., Trocóniz, I. F., Iacoboni, G., Alonso‐Martínez, C., Carreras-Soler, M.-J., Carpio, C. D. C., Farriols, A., Guerra-González, M., Rivas‐Delgado, A., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121592 · Cited by 1
“This effect is associated with the reduction of host immune competition and the stimulation of proinflammatory cytokines such as interleukin-6, interferon-γ and tumor necrosis factor-α , which drive both CAR T-cell activation and cytokine-mediated toxicities [7].”
Cunningham, D., Liu, J., Zeytin, İ. C., Cerda, D., Ghatwai, N., Courtney, A. N., Guo, L., Rathi, P., Yao, C. Q., Zhang, N., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0609 · Cited by 1
Sun, D.-Y., Wang, J.-L., Li, X., & Wang, S. (2026) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2026.04.012 · Cited by 1
“Moreover, the functional complementarity and balance be-tween CD4 + and CD8 + CAR-T cell subsets are critical for achieving optimal therapeutic outcomes [117,118].”
Blumenberg, V., Diorio, C. J., Gauthier, J., Agrusa, J. E., Dreyzin, A., Hänel, G., Espinoza-Gutarra, M. R., Geer, M. J., Perales, M., Ramakrishna, S., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.05.005 · Cited by 2
Promises and potential pitfalls of in vivo CAR gene therapy
Wagner, D. L., Elsallab, M., & Maus, M. V. (2026) · Blood · doi:10.1182/blood.2025031898 · Cited by 2
Schmid, T., Shaforostova, I., Bacher, U., Seipel, K., Kronig, M.-N., & Pabst, T. (2026) · Cancers · doi:10.3390/cancers18111787 · Cited by 2
“Higher-grade ICANS tends to occur more frequently with CAR T-cell products that use CD28 as the costimulatory domain, affecting up to 45% of patients [8,13,14].”
Cashman, H. P., & Turtle, C. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1819591 · Cited by 2
Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care
Khazal, S. J., & Mahadeo, K. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_200 · Cited by 3
[PD-1 expression, mRNA level and cytotoxicity changes in CD19CAR-T cells].
Pu, Y. D., Wang, J., Deng, Q., Zhu, H., Jiang, Y., Meng, J., & Li, Y. M. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.09.010 · Cited by 1
Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy
Greenbaum, U., Ramdial, J., Afrough, A., Alsfeld, L. C., Ghanem, S., Daher, M., Olson, A. L., Kebriaei, P., Strati, P., Steiner, R. E., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00035-8 · Cited by 1
Li, E. W., Aklilu, E., Potter, A. J., Yang, S., Ho, P. J., Vanguru, V., & Abadir, E. (2023) · Pathology · doi:10.1016/j.pathol.2023.09.008 · Cited by 1
Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Therapy and Coagulopathies
Tang, H., Li, Y. X., & Wang, S. S. Y. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_203 · Cited by 1
Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation
Feng, S., Zheng, P., Liu, H., Meiling, S., Guo, Y., Ma, L., Liu, R., Fu, Z., Yang, F., Ke, X., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1591360 · Cited by 1
Challenges and Opportunities to Improve CAR T-Cell Therapy
Balkhi, M. Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819573-4.00005-3 · Cited by 1
Perica, K., Curran, K. J., & Park, J. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00004-4 · Cited by 1
Neurotoxizität unter CAR-T-Zell-Therapie (CAR: chimärer Antigenrezeptor)
Möhn, N., Koenecke, C., & Skripuletz, T. (2020) · DGNeurologie · doi:10.1007/s42451-020-00172-y · Cited by 1
Qi, K., Cao, J., Cheng, H., Chen, M. L., Xu, W., Qiao, J., Fu, C., Pan, X.-H., Zeng, L., Li, Z. Y., et al. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.05.014 · Cited by 1
“[6] Turtle CJ, Hanafi LA, Berger C, et al.”
Background[Advances in chimeric antigen receptors T-cell therapy for B cell lymphoma].
Zhu, F., & Xu, K. (2018) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2018.12.017 · Cited by 1
“[5] Turtle CJ, Hanafi LA, Berger C, et al.”
BackgroundTreating central nervous system lymphoma in the era of precision medicine
Garcilazo-Reyes, Y. J., Ibáñez-Juliá, M.-J., Hernández-Verdín, I., Them, L. N., Younan, N., Houillier, C., Hoang‐Xuan, K., & Alentorn, A. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1777853 · Cited by 2
Greenbaum, U., Ramdial, J., Olson, A. L., Nieto, Y. L., Strati, P., Ahmed, S., Neelapu, S. S., Tummala, S., Chi, L., Shpall, E. J., et al. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.104 · Cited by 1
Toxicities of Novel Antineoplastic Therapies
Rajha, E., & Yeung, S. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-67123-5_53 · Cited by 2
CAR-T therapy in mantle cell lymphoma: a review of the current literature
Romejko‐Jarosińska, J. (2022) · Acta Haematologica Polonica · doi:10.5603/ahp.a2022.0018 · Cited by 4
Metadata
- Authors
- Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., Soma, L., Wood, B., Li, D., Heimfeld, S., Riddell, S. R., & Maloney, D. G.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Corresponding author
- Turtle, Cameron J.
- Riddell, Stanley R.
- Maloney, David G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-09-07
- Volume
- 8
- Issue
- 355
- Pages
- 355ra116-355ra116
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5045301
- OpenAlex
- W2509364267
- Semantic Scholar
- af93b35d4d1ed32f3de2e434b4049004928a60bc
- Cited by
- 1,016
- References
- 38
- Citations by year
- 2026: 37 · 2025: 60 · 2024: 101 · 2023: 78 · 2022: 113 · 2021: 120 · 2020: 153 · 2019: 139 · 2018: 121 · 2017: 85 · 2016: 6
- FWCI
- 63.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01 CA136551)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK56465)
- NCI (P30 CA15704)
- Life Science Discovery Fund
- Bezos Family Foundation
- Juno Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, non-Hodgkin lymphoma, B-cell lymphoma, CD4/CD8 ratio, lymphocyte depletion, cyclophosphamide, fludarabine, cytokine release syndrome, neurotoxicity, serum biomarkers, CAR T cell persistence, relapsed/refractory lymphoma
- MeSH terms
- Adult, Aged, Cyclophosphamide, Female, Humans, Immunotherapy, Lymphocyte Depletion, Lymphoma, Non-Hodgkin, Male, Middle Aged, Receptors, Antigen, T-Cell, Syndrome, Biomarkers, Tumor, Vidarabine, CD4-Positive T-Lymphocytes, Lymphocyte Subsets, Treatment Outcome, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.